Will the Cineworld share price double in 2022?

The Cineworld share price is up by nearly 25% already this year. Roland Head asks if he should be buying now ahead of a continued recovery.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Key points

  • Cineworld’s customers are flocking back to the big screen
  • The company says that it’s now generating positive cash flow
  • But the $8bn debt pile remains a big worry for me
  • And the threat of a C$1.2bn legal penalty can’t be ignored

Cineworld Group (LSE: CINE) shares surged on Friday after the company said that cinema revenue rose to almost 90% of 2019 levels in December. The Cineworld share price has now risen by almost 25% so far this year.

I’ve been taking a fresh look at the latest news and crunching the numbers. Should I add the shares to my portfolio in hope of a quick double bagger?

People still like the cinema

Covid-19 was a disaster for cinemas. But there’s light at the end of the tunnel. Pandemic predictions that we’d all stay at home and stream movies on television are turning out to be wide of the mark.

Cineworld said box office and concession revenue rose to 88% of 2019 levels in December. The recovery was strongest in the key US market, where cinema revenue surged to 91% of pre-pandemic levels.

Strong attendance was helped by an impressive slate of new films, including Spider-Man and No Time to Die. I’m confident this recovery will continue. More blockbuster movies are expected over the coming months, including new Batman, Top Gun and Jurassic World titles.

Money worries?

Friday’s trading update was short on financial detail. The company didn’t provide any clues on whether 2021 revenue would hit forecasts. The only thing we know is that Cineworld generated positive cash flow during the final quarter of 2021.

We’ll find out more when Cineworld issues its 2021 results on 17 March. But to be honest, we know 2021 was bad. In my view, what matters most is the outlook for 2022 and 2023.

Broker forecasts suggest that Cineworld’s recovery will accelerate this year. City analysts think that the group could generate around $420m of surplus cash in 2022. That might allow CEO Mooky Greidinger to start repaying some of the group’s $8.4bn net debt.

Earnings are also expected to recover. Broker forecasts suggest earnings of 1.5 cents per share in 2022, rising to 13.1 cents per share in 2023. That prices Cineworld shares on 36 times 2022 forecast earnings, falling to just 4.2 times projected 2023 earnings.

If the recovery goes to plan, I guess Cineworld shares might be cheap at current levels.

My verdict

Cineworld’s share price is still 40% lower than it was one year ago. One cloud hanging over the firm is a recent Canadian court ruling that it must pay rival Cineplex C$1.2bn in damages for a failed acquisition deal.

The UK company is appealing that verdict, but if Cineworld loses I think it will be difficult to find the cash without further fundraising activity.

For me, this situation is too much of a gamble. If everything goes right for Cineworld, I think the shares might double this year.

But there’s a lot that could still go wrong. And with nearly $10bn of potential liabilities, I think the shares could also fall sharply in 2022. I’ll be staying away.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »